Esomeprazole for prevention of upper gastrointestinal symptoms associated with continuous use of NSAIDs

Study identifier:D9617C00002

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

Efficacy of esomeprazole 40 mg once daily versus placebo or esomeprazole 20 mg once daily versus placebo in prevention of upper gastrointestinal symptoms associated with continuous use of NSAIDs including COX-2 selective NSAIDs

Medical condition

GERD

Phase

Phase 3

Healthy volunteers

No

Study drug

Esomeprazole

Sex

All

Actual Enrollment

334

Study type

Interventional

Age

18 Years +

Date

Study Start Date: 01 Feb 2001
Primary Completion Date: 01 Feb 2003
Study Completion Date: 01 Feb 2003

Study design

Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment

Verification:

Verified 01 Jan 2011 by AstraZeneca Pharmaceuticals

Sponsors

AstraZeneca Pharmaceuticals

Collaborators

-

Inclusion and exclusion criteria